...at MPM Capital. Prior to that, he was president and CEO of age-related disease company Centagenetix...

...advisor at MPM Capital. Before MPM, he was president and CEO of age-related disease company Centagenetix...

...Elixir Pharmaceuticals name and will focus on identifying drug targets to address diseases of aging. Centagenetix Inc....

...Mass. Business: Genomics Transition: Bard Geesaman to VP of medical from VP of informatics at Centagenetix Inc....

...Bioscience Partners. The company is the result of Wednesday's completed merger between Elixir Pharmaceuticals and Centagenetix...

...transaction. The deal combines Elixir's technology on the biology and molecular genetics of aging and Centagenetix's...

...transaction. The deal combines Elixir’s technology on the biology and molecular genetics of aging and Centagenetix’s...
...longevity. The technologies will be combined to identify drug targets to address diseases of aging. Centagenetix Inc....

...have rights to use resulting discoveries for academic purposes and will be eligible for royalties. Centagenetix Inc....

...Mass.) hired Doros Platika as CEO. Platika was formerly chairman and CEO of Curis (CRIS). Centagenetix...